Notice of AGM

Fusion Antibodies PLC
12 September 2024
 

 

12 September 2024

  

Fusion Antibodies plc

("Fusion" or the "Company")

 

Posting of Annual Report & Notice of AGM

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Annual Report and Accounts for the year ended 31 March 2024 and the Notice of the Company's Annual General Meeting ("AGM") is being posted to shareholders today.

 

A copy of the 2024 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy will shortly be available to download from the Company website here: https://www.fusionantibodies-ir.com/.

 

The AGM will be held on Tuesday, 8 October 2024 at 11.00am at the offices of Fusion Antibodies, 1 Springbank Road, Springbank Industrial Estate, Belfast BT17 0QL

 

Enquiries: 

 

Fusion Antibodies plc

           www.fusionantibodies.com

Adrian Kinkaid, Chief Executive Officer

Stephen Smyth, Chief Financial Officer

Via Walbrook PR



Fusion Antibodies interactive investor hub

https://investorhub.fusionantibodies.com/

 

 


Allenby Capital Limited

Tel: +44 (0) 20 3328 5656 

James Reeve/Vivek Bhardwaj (Corporate Finance)

Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)




 


Shard Capital Partners LLP


Damon Heath (Joint Broker)

Tel: +44 (0) 207 186 9952



 


Walbrook PR

          Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com

Anna Dunphy

                             Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

 

The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings